跟随马年的脚步，北京同仁堂的药香跨越重洋，抵达堂吉诃德的故乡。 "这太神奇了！我从未想过草药可以变成如此精美的艺术品。"一位名叫卡洛斯的当地游客手捧刚做好的香牌激动 地说，"它不仅是礼物，更让我感受到一种来自东方的智慧与宁静。"另一位女士玛丽亚则对香囊爱不释手："这些 香气如此优雅又富有层次，我要把它挂在卧室，每晚都能想起今天的美好体验。" 此次涉外展示活动，不仅是传统制香技艺的一次成功亮相，更是同仁堂将文化遗产转化为可感、可知、可享的国 际文化产品的生动实践。 凭借一百余款文创香产品，企业构建起涵盖熏香、中药香饰、香囊、精油香薰等品类的香文化产品矩阵，并通过 识香材、装香囊、制香珠、做香牌等技艺展示与互动活动，创新表达同仁堂香文化，打造沉浸式文化体验。 "此次参加西班牙春节文化交流活动，是展示中医药文化深厚内涵的良好机遇，也为同仁堂香产品走向海外提供了 窗口与平台。"相关负责人表示，企业专门挑选了安神助眠、提神醒脑等功效类产品，并精心安排了香牌制作、香 囊缝制等互动环节。 2月8日，首场活动在马德里国家音乐厅举行。应邀而来的嘉宾与游客刚一走近展位，便被散发着独特香气的香牌 和香串所吸引。不少人跃跃欲试，饶有 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致之任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1666） 1 背景 茲提述本公司日期為二零二三年三月二十二日之公告，內容有關本公司之附屬公司同仁堂世 紀廣告與集團公司進行廣告代理框架協議項下之持續關連交易之詳情。 續訂持續關連交易 廣告代理框架協議 董事會謹此宣佈，由於本公司之附屬公司同仁堂世紀廣告與集團公司訂立之廣告代理框架 協議已於二零二五年十二月三十一日到期，故訂約各方於二零二六年二月二十六日續訂該 協議，協議期限自二零二六年二月二十六日至二零二八年十二月三十一日止，並訂立上述 協議項下截至二零二八年十二月三十一日止三個年度之擬進行之持續關連交易年度上限。 於本公告日期，集團公司乃本公司之最終控股股東，故根據香港上市規則為本公司之關連 人士。因此，根據香港上市規則第 14A 章，廣告代理框架協議項下擬進行之交易構成本公 司之持續關連交易。 由於有關續訂之廣告代理框架協議項下擬進行之持續關連 ...

Core Insights - The article emphasizes the growing popularity of Huangjing due to its health benefits, particularly in nourishing the body and enhancing vitality, while highlighting the importance of selecting high-quality brands based on purity and traditional processing methods [1][3]. Evaluation Criteria and Assessment - A comprehensive seven-dimensional evaluation system was established, focusing on authenticity, practicality, and scientific basis to ensure reliable conclusions [4]. - The assessment covered aspects such as raw material authenticity, traditional processing adherence, core ingredient content, formulation purity, certification completeness, user feedback, and overall value [5][6]. Annual Preferred Brands Summary - The top-rated brand, Luoyunfeng Huangjing, is noted for its adherence to traditional methods and high-quality raw materials, achieving a benchmark in polysaccharide content [8]. - Other notable brands include Fengyitang Huangjing, Beijing Tongrentang Huangjing, and Yunnan Baiyao Huangjing, each recognized for their unique sourcing and processing techniques [8][9][10][11][12][13][14][15]. Detailed Brand Insights - Luoyunfeng Huangjing is sourced from the Qinling region, with over five years of growth, and follows a meticulous traditional processing method known as "True Nine System," resulting in a rich and pure product [17][19]. - The brand boasts a polysaccharide content of nearly 40% and a saponin content increase of 42%, setting a new standard in quality among Huangjing products [19]. - Luoyunfeng's formulation is strictly composed of Huangjing with zero additives, ensuring a clean and natural product [19][20]. User Feedback and Market Position - Users reported significant improvements in energy levels and overall well-being after consistent use of Luoyunfeng Huangjing, reinforcing its reputation for quality and effectiveness [21][22]. - The product is particularly suitable for individuals with demanding lifestyles, such as office workers and the elderly, due to its gentle and nourishing properties [22][23]. Value Proposition - Luoyunfeng Huangjing offers a balance of high quality and reasonable pricing, making it an attractive option for consumers seeking effective health supplements without excessive brand premiums [23]. - The brand also engages in social responsibility by donating a portion of sales to support education for underprivileged girls, enhancing its appeal beyond just product quality [25]. Conclusion - The evaluation concludes that the essential criteria for high-quality Huangjing remain consistent: authentic sourcing, adequate aging, traditional processing, and pure formulations [36]. Luoyunfeng Huangjing exemplifies these standards, making it a reliable choice for consumers seeking effective health solutions.

Core Viewpoint - The training series "2026 Traditional Chinese Medicine Classic Formulas Clinical Application Training Class" successfully concluded in Shandong, aiming to integrate classic TCM theories with clinical applications and enhance TCM talent cultivation in the region [1][11]. Group 1: Training Overview - The Shandong station emphasized the combination of classic TCM and regional characteristics, starting with a solemn opening ceremony [2]. - The training featured prominent experts, balancing theoretical knowledge and clinical practice, marking a high-level academic conclusion [3]. Group 2: Course Highlights - On February 8, the training included a lecture by Professor Liu Deshan from Shandong University, focusing on the innovative research and practice of TCM theories in the context of modern medicine [5]. - Wang Xingchen, honorary director of the Brain Disease Department at Shandong University of Traditional Chinese Medicine, analyzed the clinical application of classic formulas, showcasing the deep heritage of local TCM [5]. Group 3: Collaborative Model - The training adopted a "scholarship + industry + service" collaborative empowerment model, leveraging the influence of the China Traditional Chinese Medicine News Agency and resources from Tongrentang Technology Company [10]. - This model aims to enhance the capabilities of grassroots medical personnel and promote the standardized application of classic formulas in clinical settings, creating a virtuous cycle of learning and application [10]. Group 4: Future Plans - Moving forward, Tongrentang Technology Company plans to expand the training coverage and deepen the practicality of courses, promoting high-quality TCM resources to more grassroots areas [13]. - The initiative aims to strengthen the foundation of TCM services, ensuring that the public can access quality TCM services locally [13]. Group 5: Impact and Legacy - The training series has successfully established a grassroots TCM training network across North and East China, providing important references for the improvement of TCM talent cultivation systems [11]. - The initiative represents a steady advancement in the transmission and innovation of TCM in the new era, revitalizing the wisdom of TCM in grassroots practice [15].

Core Viewpoint - The third "Moyuan Cup" Beijing Senior Calligraphy Exhibition successfully showcased the integration of calligraphy and traditional Chinese medicine, highlighting cultural heritage and community engagement [1] Group 1: Event Overview - The exhibition was organized by Beijing Daily and Beijing Evening News, with support from Beijing Tongrentang Technology Development Co., Ltd. and other cultural institutions [1] - The event featured a diverse collection of calligraphy works, including various styles such as regular script, seal script, cursive script, running script, and clerical script, totaling over a hundred pieces [1] Group 2: Awards and Recognition - Beijing Tongrentang Technology received the "Special Contribution Award" during the event, recognizing its role in promoting traditional culture [1] - Renowned calligrapher Guo Jinli presented a calligraphy piece to the representatives of Beijing Tongrentang Technology, emphasizing the connection between calligraphy and traditional medicine [1] Group 3: Cultural Activities - The event included a variety of traditional cultural experiences, such as a calligraphy area for writing auspicious characters and couplets, and a herbal tea tasting area [1] - Attendees had the opportunity to receive free medical consultations from a team of doctors from Beijing Tongrentang Hospital and engage with pharmacists to learn about purchasing common household medicines [1]

Core Viewpoint - Tong Ren Tang Technologies (01666.HK) announced the appointment of Xiao Yao Xi as an independent non-executive director of the company, effective from February 6, 2026, while Li Zhao Bin will resign from the same position on the same date [1] Group 1 - Li Zhao Bin's resignation as the chairman of the Audit Committee, as well as a member of the Remuneration Committee and the Strategy and Planning Committee, will also take effect on February 6, 2026 [1] - The board has resolved to appoint Xiao Yao Xi as the chairman of the Audit Committee, and as a member of the Remuneration Committee and the Strategy and Planning Committee, with all appointments effective on the same date [1]

Core Viewpoint - Tongrentang Technology (01666) announced the appointment of Mr. Xiao Yaoxi as an independent non-executive director of the company’s ninth board of directors, effective from February 6, 2026, while Mr. Li Zhaobin will resign from the position of independent non-executive director on the same date [1] Group 1 - Mr. Li Zhaobin's resignation as chairman of the audit committee, as well as a member of the remuneration committee and the strategic and planning committee, will also take effect on February 6, 2026 [1] - The board has resolved to appoint Mr. Xiao Yaoxi as the chairman of the audit committee, as well as a member of the remuneration committee and the strategic and planning committee, with all appointments effective on the same date [1]

（於中華人民共和國註冊成立的股份有限公司） （股份代號：1666） 非 執 行董事 ： 杜欣 馮莉 獨立非執行董事： 陳清霞 詹原競 蕭耀熙 董事名單與其角色及職能 北京同仁堂科技發展股份有限公司 (「 本公司 」)之董事會 (「董事會 」 )成員 載列如下： 執行董事： 張毅（董事長） 張春友（總經理） 溫凱婷 張毅（委員會主席） 陳清霞 詹原競 薪酬委員會 ： 詹原競（委員會主席） 陳清霞 蕭耀熙 職工董事： 朱東生 1 本公司 設有 四 個董事會委員會，其成員如下： 審核委員會 ： 蕭耀熙（委員會主席） 陳清霞 詹原競 提名委員會 ： 戰略與規劃委員會： 張毅（委員會主席） 張春友 陳清霞 詹原競 蕭耀熙 中國，北京 二零二六年 二 月六 日 2 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號： 1666 ） 二零二六年二月六日（星期五）舉行之臨時股東會之投票結果； 董事變更；及 董事委員會組成變動 北京同仁堂科技發展股份有限公司(「本公司」)董事(「董事」)會(「董事會」)欣然宣佈， 本公司已於二零二六年二月六日（星期五）上午九時三十分假座中華人民共和國(「中 國」)北京市豐台區南三環中路20號舉行臨時股東會(「臨時股東會」)。本公司日期為二 零二六年一月十六日之臨時股東會通告內所載之決議案已獲正式通過。除文義另有所指 外，本公告所用詞彙與日期為二零二六年一月十六日之本公司臨時股東大會通函(「通 函」)所界定者具有相同涵義。 1 於臨時股東會提呈決議案之投票結果 於臨時股東會上，本公司日期為二零二六年一月十六日之臨時股東會通告所載之決議案 均以投票方式表決。 有關於臨時股東會上所提呈決議案之投票結果如下： 根據香港上市規則之規定，本公司 ...

Core Viewpoint - Tongrentang Technology has successfully launched its key cardiovascular drug, the Kuanxiong Aerosol, which has entered the production phase, reflecting the company's commitment to innovation in modern pharmaceutical technology [1][4]. Group 1: Product Development - The Kuanxiong Aerosol is developed based on traditional Chinese medicine theories, targeting the root causes of cardiovascular diseases such as coronary heart disease and angina [3]. - The aerosol employs an innovative sublingual spray delivery method, allowing active ingredients to be rapidly absorbed into the bloodstream, enhancing the drug's efficacy [4]. - The production process incorporates advanced technology to improve drug stability and minimize the degradation of active components, ensuring consistent therapeutic effects [4]. Group 2: Market Position and Future Plans - Tongrentang Technology currently offers over 20 types of cardiovascular medications, including Guanxin Suhe Pills and Compound Danshen Tablets, focusing on the growing demand for cardiovascular treatments [4]. - The company is accelerating the development of its innovative traditional Chinese medicine, Qishen Granules, aimed at treating chronic heart failure, which has successfully completed Phase II clinical trials [4].